NHS National Framework Agreement for the Supply of products for the management of Hereditary Angioedema

Tender description

National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for a list of the purchasing points. Lot 1: Lot 1 – C1 Esterase – Recombinant IV (acute treatment) NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.<br/><br/>Additional CPV Codes:<br/>33141520 – Plasma Extracts<br/>33141510 – Blood Products Lot 3: Lot 3 - C1 Esterase – Plasma derived IV (prophylaxis treatment) NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.<br/><br/>Additional CPV Codes:<br/>33141520 – Plasma Extracts<br/>33141510 – Blood Products Lot 6: Lot 6 - Lanadelumab NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.<br/><br/>Additional CPV Codes:<br/>33141520 – Plasma Extracts<br/>33141510 – Blood Products Lot 7: Lot 7 - Berotralstat NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.<br/><br/>Additional CPV Codes:<br/>33141520 – Plasma Extracts<br/>33141510 – Blood Products Lot 2: Lot 2 - C1 Esterase – Plasma derived IV (acute treatment) NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.<br/><br/>Additional CPV Codes:<br/>33141520 – Plasma Extracts<br/>33141510 – Blood Products Lot 4: Lot 4 - C1 Esterase – Plasma derived Subcut (prophylaxis treatment) NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.<br/><br/>Additional CPV Codes:<br/>33141520 – Plasma Extracts<br/>33141510 – Blood Products Lot 5: Lot 5 - Icatibant NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.<br/><br/>Additional CPV Codes:<br/>33141520 – Plasma Extracts<br/>33141510 – Blood Products